Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 533

Results For "CE"

8169 News Found

Neuroscientist Abhijeet Satani unveils Cognitively Operated System in Ahmedabad
News | September 05, 2023

Neuroscientist Abhijeet Satani unveils Cognitively Operated System in Ahmedabad

The cognitively operated system is a mother patent invention, first launched in India


Amgen settles with FTC over US$28 billion deal
Policy | September 04, 2023

Amgen settles with FTC over US$28 billion deal

Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products


BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData
News | September 03, 2023

BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData

BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials


India's digital startup ecosystem a catalyst for global healthcare transformation: Piyush Goyal
Digitisation | September 02, 2023

India's digital startup ecosystem a catalyst for global healthcare transformation: Piyush Goyal

Robots make it to the healthcare conference panel, reflecting the future potential of technology


Jupiter Life Line Hospitals’ IPO to open on Sept. 6
News | September 02, 2023

Jupiter Life Line Hospitals’ IPO to open on Sept. 6

Sets price band at ?695 to ?735 per Equity Share


Biocon acquires oral solid dosage manufacturing facility of Eywa Pharma for US$7.7 million
News | September 02, 2023

Biocon acquires oral solid dosage manufacturing facility of Eywa Pharma for US$7.7 million

The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year


Sanofi, Meningitis Research Foundation and CoMO launch awareness initiative on meningitis
News | September 01, 2023

Sanofi, Meningitis Research Foundation and CoMO launch awareness initiative on meningitis

Meningitis still affects more than 2.5 million people globally each year


USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes
Drug Approval | September 01, 2023

USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes

Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia